Your session is about to expire
← Back to Search
RBM Regimen for Multiple Myeloma and Lymphoma
Study Summary
This trial is testing a new combination chemo-immuno therapy called RBM. It is made of up of different drugs and involves reinfusing the participants own stem cells. Compared to the standard BEAM regimen, this RBM regimen may or may not be less effective, but will likely have fewer side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lymphoma has worsened since my last treatment, or I've had a stem cell transplant, or my previous treatment included bendamustine, or I've had a heart attack or stroke in the last 6 months.I have been diagnosed with multiple myeloma, relapsed/refractory DLBCL, or transformed indolent lymphoma.I have multiple myeloma or B-cell non-Hodgkin lymphoma.
- Group 1: rituximab, bendamustine & melphalan and ASCT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this scientific investigation presently have any open recruitment opportunities?
"This particular trial has already closed its recruitment period, which began on November 20th 2017 and ended August 10th 2022. If you're seeking alternative research opportunities, there are currently 2408 clinical trials recruiting for lymphoma patients and 546 studies aiming to enrol those undergoing Autologous Stem Cell Transplantation (ASCT)."
How many individuals have been registered to take part in this medical experiment?
"This clinical trial has ceased to accept new participants. Initially posted on the 20th of November 2017 and last updated on August 10th 2022, it is no longer enrolling patients for this study. However, 2408 studies related to lymphoma as well as 546 trials involving Autologous Stem Cell Transplantation (ASCT) are still recruiting individuals at present."
To what purpose does Autologous Stem Cell Transplantation (ASCT) generally apply?
"Autologous Stem Cell Transplantation (ASCT) is an intervention commonly prescribed to treat b-cell lymphomas, polyangium, multiple myeloma and even rheumatoid arthritis."
Share this study with friends
Copy Link
Messenger